

Reboxetine

General:

Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and attention-deficit hyperactivity disorder. It is a norepinephrine reuptake inhibitor (NRI) but it does not inhibit the reuptake of serotonin, therefore it can be safely combined with a selective serotonin reuptake inhibitor.

Common side effects of reboxetine are consistent with its anticholinergic properties, and include: dry mouth, constipation, headache, drowsiness, diz-ziness, excessive sweating and insomnia. Hypertension has been observed infrequently. Because of its reliance on CYP3A4, reboxetine O-desethylation is markedly inhibited by papaverine and ketoconazole. Reboxetine also is an intermediate-level inhibitor of P-glycoprotein, which gives it the potential to interact with cyclosporine, tacrolimus, paroxetine, sertraline, quinidine, fluoxetine, fluvoxamine. The potency and duration of the effects of benzodi-azepines can be increased because reboxetine interferes with their excre-tion.

Material: 1 ml serum

TAT: 7-10 days*

Method: LCMS

Units: µg/l

Ref.- range: 60.0 - 350.0

For complete list of laboratory test offered at Freiburg Medical Laboratory, please visit
<http://www.fml-dubai.com/parameter-listings/>